×

Biotech and Pharmaceuticals Medicine

  • March 24- Xenon Pharmaceuticals Inc's shares tumbled 45 percent in premarket trading on Friday after the drug developer said it would discontinue developing its acne drug as it failed to meet the main goal in a mid-stage study. Acne is the most common skin condition in the United States, affecting up to 50 million Americans annually, according to the American...

  • March 24- Xenon Pharmaceuticals Inc said on Friday it would abandon its acne drug, after it failed to meet the main goal in a mid-stage study. The drug, XEN801, which was tested against a placebo, did not induce a statistically significant effect in treating moderate to severe facial acne. Acne is the most common skin condition in the United States, affecting up to 50...

  • A first responder for Livingston County Michigan, draws the blood of Amaria Roberson, age 5 of Flint, to screen her blood for lead on January 26, 2016 at Eisenhower Elementary School in Flint, Michigan. Free lead screenings are performed for Flint children 6-years-old and younger, one of several events sponsored by Molina Healthcare following the city's water contamination and federal state of emergency.

    As Republicans tried to muster support for their health-care bill on Thursday, one insurance executive told CNBC the measure is a bad idea.

  • The Food and Drug Administration said it approved Bavencio, known chemically as avelumab, to treat metastatic Merkel cell carcinoma in patients 12 years and older. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said in a statement. About 1,600 people in the United States are diagnosed with MCC every year, according to the National Cancer...

  • March 22- Ultragenyx Pharmaceutical Inc said its drug to treat patients with seizures did not meet the main goal in a mid-stage study, sending its shares down 6.2 percent in after-market trading on Wednesday. The company said the study did not show statistical significance in reducing the frequency of seizures among patients treated with the drug compared to...

  • BOSTON— The former head of a Massachusetts pharmacy was acquitted Wednesday of murder allegations but convicted of racketeering and other crimes in a meningitis outbreak that was traced to fungus-contaminated drugs and killed 64 people across the country. Indiana, Michigan and Tennessee were hit hardest. Joan Peay, 76, of Nashville, Tennessee, suffered two...

  • *Trial failure trims Novartis blockbuster hopefuls to 12. *Some traders say failed drug had $2 bln/ year potential. ZURICH, March 22- Novartis's heart failure drug serelaxin flopped in a late-stage trial by not cutting cardiovascular death or slowing disease progression, marking the likely demise of a drug hopeful the Swiss firm had promoted as a potential...

  • ZURICH, March 22- Novartis' efforts to expand its heart treatment franchise beyond its flagship Entresto business suffered a blow when it announced on Wednesday its acute heart failure drug serelaxin had failed in a late-stage trial. Serelaxin, once seen a potential blockbuster, suffered a string of setbacks in 2014 when European Union health regulators and...

  • TRENTON, N.J.— U.S. regulators have approved the first new drug in a decade for Parkinson's disease, a chronic neurological disorder that causes tremors and movement difficulties. The Food and Drug Administration said Tuesday that it has approved Xadago for use when a patient's regular medicines aren't working well. According to the FDA, adding Xadago to...

  • Biogen wins patent decision

    CNBC's Meg Tirrell reports on the victory for Biogen in its patent case over its Multiple Sclerosis drug.

  • *Trial positive despite negative interim data. *To submit marketing application for mono, combo therapy in 2017. March 20- Eli Lilly and Co's combination of its experimental breast cancer drug and another widely used treatment slowed disease progression in patients who relapsed or did not benefit enough when treated with the anti-estrogen therapy.

  • *Co to discuss next steps with FDA, looks for strategic partner. The company's stock jumped about 19 percent to $19.50 in premarket trading on Monday. Everyday, 91 Americans die of opioid overdose, the U.S. Centers for Disease Control and Prevention estimates.

  • March 20- Nektar Therapeutics said its experimental opioid, designed to achieve pain relief without the high levels of euphoria that can lead to abuse and addiction with existing opioids, succeeded in a key late-stage study. U.S. regulators and lawmakers have taken a number of steps to control the supply of opioids as the country is engulfed in an epidemic of...

  • Abemaciclib, which was granted U.S. Food and Drug Administration breakthrough therapy status for breast cancer in 2015, is also being tested for use in lung cancer. After skin cancer, breast cancer is the most common cancer in women in the United States, according to the U.S. Centers for Disease Control and Prevention. About 40,610 women will die from breast...

  • March 20- Eli Lilly and Co said a combination of its experimental breast cancer drug and another widely used treatment slowed disease progression in a key study in patients who had relapsed or did not derive enough benefit from anti-estrogen therapy. Lilly's drug, abemaciclib, is from the same new class of breast cancer treatments as Pfizer Inc's recently...

  • March 20- U.S. drugmaker Eli Lilly and Co said on Monday a combination of its experimental breast cancer drug and chemotherapy slowed disease progression in patients who had relapsed or did not derive enough benefit from prior treatment.

  • WASHINGTON, March 17- Amgen Inc's $14,000 cholesterol drug Repatha cut the risk of heart attack and stroke by over 20 percent in patients with heart disease, but results from a highly anticipated study fell short of investor expectations and shares dropped 6 percent. Amgen acknowledged during a presentation for investors that it is already selling Repatha at...

  • WASHINGTON, March 17- Amgen Inc's $14,000 cholesterol drug Repatha cut the risk of heart attack and stroke by over 20 percent in patients with heart disease, but results from a highly-anticipated study fell short of investor expectations and shares dropped 6 percent. Sales of Repatha, and its competitor Praluent from Regeneron Pharmaceuticals and Sanofi,...

  • WASHINGTON, March 17- A long-acting new type of drug being developed by Medicines Co cut levels of "bad" LDL cholesterol in half in high-risk heart patients with no serious safety issues, according to data from a Phase II trial presented on Friday. Despite the positive results, Medicine Co shares fell 14.6 percent after highly-anticipated data from Amgen Inc's...

  • WASHINGTON, March 17- Amgen Inc's cholesterol drug Repatha cut the risk of heart attacks and strokes by over 20 percent in patients with heart disease, but the extent of its benefits in the highly-anticipated study disappointed investors and shares fell 6 percent. Sales of Repatha, and its competitor Praluent from Regeneron Pharmaceuticals and Sanofi, have...